Clinical Trial Update: Predicting Response to Neoadjuvant ATEZOLIZUMAB Plus Carboplatin/Nab Paclitaxel in Resectable Non-squamous NSCLC [Phase 2]

View source ↗

Summary

A Phase 2 trial is evaluating whether combining atezolizumab with carboplatin and nab-paclitaxel as neoadjuvant therapy can predict response in resectable non-s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• CARBOPLATIN (Carboplatin)
• Nab-paclitaxel (paclitaxel protein-bound)

Snippet

Sponsor: University Hospital Heidelberg | Conditions: NSCLC Stage II, NSCLC, Stage IIIA | Phase 2 | Status: RECRUITING